Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticosteroid-induced osteoporosis

J C Joseph1

  • 1Department of Pharmacy Practice, College of Pharmacy, Washington State University, Spokane 99204.

American Journal of Hospital Pharmacy
|January 15, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose optimisation of intravenous tranexamic acid for elective hip and knee arthroplasty: The effectiveness of a single pre-operative dose.

Bone & joint research·2017
Same author

Compatibility of nebulizer solution admixtures.

The Annals of pharmacotherapy·1997
Same author

Management of hypertension in the diabetic patient.

Clinical pharmacy·1990
Same author

Moisture loss from small-volume polyvinyl chloride containers removed from overwraps.

American journal of hospital pharmacy·1990
Same author

Comparison of protein values in cerebrospinal fluid by nephelometry and radial immunodiffusion.

Annals of clinical and laboratory science·1979
Same author

Changes in plasma proteins during pregnancy.

Annals of clinical and laboratory science·1978
Same journal

National health care reform, Part 2: Response to pharmacists.

American journal of hospital pharmacy·1994
Same journal

Validity of originality assessment.

American journal of hospital pharmacy·1994
Same journal

Unit dose dispensing of chromic phosphate P 32 suspension.

American journal of hospital pharmacy·1994
Same journal

Hydralazine injection still available.

American journal of hospital pharmacy·1994
Same journal

Improved extemporaneous formulation of cyclosporine ophthalmic drops.

American journal of hospital pharmacy·1994
Same journal

Paclitaxel diluent and the case of the slippery spike.

American journal of hospital pharmacy·1994
See all related articles

Corticosteroid-induced osteoporosis is a serious condition linked to prolonged use. Prevention involves minimizing corticosteroid exposure and addressing risk factors, while treatment options are still under investigation.

Area of Science:

  • Endocrinology
  • Rheumatology
  • Pharmacology

Background:

  • Prolonged corticosteroid administration is a significant cause of morbidity and mortality due to osteoporosis.
  • Key risk factors include cumulative doses over 10 g, age over 50, and pre-existing low bone mass.

Purpose of the Study:

  • To review the pathogenesis, prevention, and treatment of corticosteroid-induced osteoporosis.
  • To highlight the limitations in current long-term studies for prevention and treatment.

Main Methods:

  • Review of existing literature on corticosteroid-induced osteoporosis.
  • Identification of risk factors and preventive measures.
  • Evaluation of current and potential therapeutic interventions.

Main Results:

Related Experiment Videos

  • Preventive measures include modifying risk factors and using the lowest effective corticosteroid dose for the shortest duration.
  • Routine use of certain supplements and medications alone is not recommended for prevention or treatment.
  • Intranasal calcitonin and pamidronate show potential for future treatment.

Conclusions:

  • Estrogen replacement therapy is recommended for postmenopausal women on corticosteroids.
  • Deflazacort presents a potential alternative corticosteroid therapy.
  • Further long-term, controlled trials are essential to validate treatment effectiveness and monitoring methods.